PHILADELPHIA, February 02, 2016 — Premier Research announces the appointment of Michael King Jolly, Pharm.D., as Senior Vice President. In this newly created position, Dr. Jolly oversees drug development partnerships and develops innovative offerings for the company, a leader in clinical development for the biotech and specialty pharma sectors.
With more than 30 years of experience in clinical research and drug development, Dr. Jolly comes to Premier Research from Quintiles, where he founded and was Senior Vice President of the company’s Quintiles Innovation unit. He served as Senior Vice President for Drug Development Partnerships at NovaQuest, the strategic partnering arm of Quintiles, and as the company’s Vice President for cardiovascular therapeutics and head of medical operations.
At King Pharmaceuticals, Dr. Jolly served as Executive Vice President for R&D, overseeing all clinical and preclinical research. He also was a Clinical Research Scientist and Associate Director at Burroughs Wellcome, where he began his pharmaceutical career.
Dr. Jolly holds a Doctor of Pharmacy degree from the University of Texas-Austin and a bachelor’s degree in zoology from the University of North Carolina-Chapel Hill, and is a graduate of the Burroughs Wellcome Management Institute. He teaches at Duke University Medical School and the School of Pharmacy at the University of North Carolina-Chapel Hill.
About Premier Research
Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs with a special focus on addressing unmet needs in such areas as analgesia, CNS, rare diseases, medical device and diagnostics, pediatric and oncology research. Premier Research operates in 84 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively.